Most people who would benefit from joining a clinical trial never do, not because they are ineligible or uninterested, but because they do not know where to look, what the process involves, or how to evaluate whether a specific trial is appropriate for their situation. The gap between the number of trials actively recruiting participants at any given time and the number of people who find and join them is one of the most consequential inefficiencies in medical research. Clinical trial enrollment shortfalls are responsible for delayed drug approvals, underpowered studies that cannot detect real treatment effects, and the abandonment of promising research that ran out of time or funding before reaching its enrollment target. Understanding how to navigate the trial finding and joining process is not merely useful for the individual who might benefit from participation. It contributes directly to the scientific enterprise that produces the treatments everyone will eventually depend on.

Where Clinical Trials Are Listed and How to Search Them

The starting point for finding any clinical trial in the United States is ClinicalTrials.gov, a database maintained by the National Library of Medicine that lists every federally and privately funded trial conducted in the United States and many international trials as well. As of 2024, the database contains records for over 470,000 studies across every medical condition and therapeutic area. Every listed trial includes its current recruitment status, its purpose and design, its eligibility criteria, its primary and secondary endpoints, its sponsor, its locations, and the contact information for the research team managing enrollment.

Searching effectively on ClinicalTrials.gov requires understanding a few navigation points that are not immediately obvious to first-time users. The basic search bar accepts condition names, drug names, intervention types, and researcher names. The advanced search function allows filtering by recruitment status, which is the most important filter to apply first. Selecting recruiting as the status filter eliminates all trials that are completed, not yet recruiting, or no longer enrolling, which represent the majority of records in the database. Adding your zip code and a distance radius narrows results to trials with sites near your location or, for decentralized trials, trials that operate remotely.

The condition search term matters significantly for how many relevant results appear. Searching type 2 diabetes returns different results than searching insulin resistance or metabolic syndrome, even though these conditions overlap substantially. Using multiple condition-related terms across separate searches captures a more complete picture of available trials than any single search term produces. The National Institutes of Health maintains condition-specific research portals that link to relevant ClinicalTrials.gov searches for major disease areas and are worth consulting alongside direct database searches for people with specific diagnoses.

International trial databases including the EU Clinical Trials Register for European trials and the WHO International Clinical Trials Registry Platform list trials not registered on ClinicalTrials.gov and are relevant for people willing to consider participation outside their home country or for people researching the global evidence base for a specific treatment.

Understanding the Eligibility Criteria

Every clinical trial has a set of eligibility criteria that define who can and cannot participate, and these criteria are the first and most important filter to apply when evaluating whether a specific trial is right for you. Eligibility criteria exist for two reasons. The first is scientific. To detect a real treatment effect in a study population, the population needs to be sufficiently homogeneous that variation between participants does not obscure the signal the trial is designed to measure. The second is ethical. Certain medical conditions, medications, or demographic characteristics create risks that make participation unsafe for specific individuals, and the exclusion criteria protect those individuals from harm.

Eligibility criteria are divided into inclusion criteria, which must be met to qualify, and exclusion criteria, which disqualify an otherwise eligible person if present. Common inclusion criteria include age range, diagnosis type and severity, disease duration, prior treatment history, and specific laboratory value ranges. Common exclusion criteria include pregnancy, certain existing medications that would interact with the study intervention, specific comorbid conditions that would confound the results or elevate risk, and prior participation in related trials.

Reading eligibility criteria carefully before contacting a research team saves time for both the potential participant and the trial staff. Many people who contact research teams are immediately screened out by a single exclusion criterion that is clearly stated in the listing. The most common disqualifying factors are current medication use, recent participation in another clinical trial, and laboratory values outside the specified range. Identifying these potential disqualifiers before making contact allows for a more productive initial conversation with the research team.

Not meeting the eligibility criteria for one trial does not mean no trial exists for which you qualify. Trials studying the same condition often have different eligibility parameters based on their specific research question, their phase of development, and the population characteristics most relevant to what they are trying to measure. A person excluded from a Phase 3 trial for a specific drug because of their medication history may qualify for a Phase 2 trial studying a different compound for the same condition, or for a behavioral or device trial that has no medication-related exclusion criteria at all.

How to Contact a Research Team

The contact information listed on every ClinicalTrials.gov record is the direct starting point for expressing interest in a specific trial. Most trial listings include either a central contact person at the sponsoring organization, a site-specific contact at the recruiting location, or both. The initial contact is typically made by phone or email, and the content of that first communication should be brief and specific. State the name of the trial by its NCT number, the unique identifier assigned to every ClinicalTrials.gov record, your general health situation in one to two sentences, and your question about whether pre-screening is available.

The research coordinator who manages enrollment is the person most participants interact with first, and they are familiar with the eligibility criteria in detail. A ten-minute phone conversation with a research coordinator is often sufficient to determine whether formal pre-screening is worth pursuing, because coordinators can identify obvious disqualifying factors quickly and advise potential participants whether to proceed or whether a different trial might be more appropriate for their situation.

Pre-screening is an informal process, typically a brief questionnaire or phone interview, that assesses whether a potential participant is likely to meet the formal eligibility criteria before the more resource-intensive formal screening process begins. It is not binding in either direction. Passing pre-screening does not guarantee enrollment, and the information shared during pre-screening does not become part of the trial record or affect the potential participant’s clinical care in any way.

Formal screening involves a clinical evaluation that may include physical examination, laboratory tests, imaging studies, and a review of medical history records. The specific screening procedures depend entirely on what the trial protocol requires to confirm eligibility. Some trials conduct all screening remotely through telehealth visits and laboratory orders sent to local facilities. Others require an in-person visit to the trial site. The informed consent process, which is a legal and ethical requirement that must be completed before any screening procedures begin, gives potential participants a complete picture of what participation involves before they commit to anything.

What the Informed Consent Process Involves

The informed consent process is not a single form signed at the end of a presentation. It is a structured conversation between the research team and the potential participant, conducted at a pace determined by the participant’s need for information and time for reflection. The Food and Drug Administration and the Office for Human Research Protections both maintain regulatory oversight of the informed consent process, which must meet specific content and procedural standards to be considered legally valid.

The informed consent document covers the purpose of the study, the specific procedures involved, the frequency and duration of visits or contacts, the known risks and potential benefits of participation, the alternatives to participation including standard treatment options, how personal data will be collected, stored, and used, and the participant’s rights including the right to withdraw at any time without penalty or effect on standard medical care.

Reading the informed consent document thoroughly before signing it is not only appropriate but expected. Bringing a family member or trusted person to the consent conversation, asking the research team to explain anything that is unclear, requesting time to consult with a personal physician before deciding, and requesting a copy of the signed document to keep for personal records are all standard practices that research teams are accustomed to accommodating. A research team that discourages questions or pressures a potential participant toward rapid consent is exhibiting a red flag that warrants caution and should be reported to the trial’s institutional review board (IRB) if it occurs.

What Participation Actually Looks Like Week to Week

The day-to-day experience of clinical trial participation varies enormously depending on the trial phase, the intervention being studied, and the trial’s design. What happens inside each trial phase described in the phase explainer is the foundation for understanding what any specific trial will require, but the practical weekly experience is shaped by the protocol in ways that the phase description alone does not capture.

Most trials involve a combination of scheduled site visits, remote check-ins, patient-reported outcome surveys completed through an app or web portal, and laboratory tests or monitoring procedures conducted either at the trial site or at a local laboratory. The frequency of contact is highest in Phase 1 and early Phase 2, where safety monitoring requires close observation, and typically lower in Phase 3, where participants may have monthly or quarterly visits after an initial intensive period.

Transportation, parking, and time away from work are practical considerations that research teams are experienced in discussing with participants. Many trials offer compensation for travel expenses, and some offer stipends for time and inconvenience that vary by trial budget and local standards. Federal regulations prohibit compensation amounts that are so large they constitute undue inducement, meaning payment that would cause a person to overlook real risks they would otherwise decline, but reasonable compensation for time and expenses is standard practice and should not be a barrier to asking about it.

Using Patient Advocacy Organizations and Disease-Specific Registries

Beyond ClinicalTrials.gov, disease-specific patient advocacy organizations frequently maintain their own trial matching resources that are tailored to their specific community and updated more responsively to new trial openings than a general database can achieve. Organizations including the Leukemia and Lymphoma Society, the Alzheimer’s Association, the American Diabetes Association, and hundreds of condition-specific organizations operate trial finder tools, patient navigators, and community forums where members share experiences with specific trials and research teams.

Patient registries are databases of people with specific conditions who have consented to be contacted about relevant research opportunities. Registering with a condition-specific registry is one of the most passive and most effective ways to be notified of new trials for which you may qualify, because the matching is done by the registry rather than requiring you to actively search. ResearchMatch, a national registry funded by the National Institutes of Health, connects volunteers with researchers across a broad range of health conditions and is open to both healthy volunteers and people with specific diagnoses.

Discussing trial participation with your treating physician is worth doing regardless of whether you have already identified a specific trial of interest. Physicians are aware of trials recruiting through their institution and through professional networks that may not yet appear in public databases. They are also positioned to evaluate whether a specific trial’s intervention is appropriate given your complete medical history, a perspective that complements but does not replace the eligibility assessment the research team will conduct. What happens in each trial phase is the essential background knowledge that makes those physician conversations more productive, because it allows you to ask specific questions about what phase a trial is in, what that means for the certainty of the evidence behind the intervention, and what the scientific purpose of your participation would be.